Drug Trial Radar · NCT05186753
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
237
Planned (sponsor's estimate)
Start
Jun 27, 2022
Primary completion
May 22, 2025
Study completion Jan 2030
Sponsor
- Lead sponsor
- Cogent Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdvSM), including indolent systemic mastocytosis and smoldering systemic mastocytosis, whose symptoms are not adequately controlled by BSC. This study will be conducted in three parts. Patients in Parts 1a, 1b and 2 will receive bezuclastinib or placebo, and may roll over onto Part 3 to receive treatment with bezuclastinib. Additionally, a substudy of subjects will investigate the efficacy, safety, and tolerability of bezuclastinib in patients who are experiencing inadequate symptom control with avapritinib.
Conditions
- SSM
- Mastocytosis, Indolent
- Mastocytosis, Systemic
- Mastocytosis
- ISM
- BMM
- Smoldering Systemic Mastocytosis
- Bone Marrow Mastocytosis
Interventions
Bezuclastinib Tablets (Formulation A)Drug
Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
Bezuclastinib Tablets (Formulation B)Drug
Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
Placebo TabletsDrug
Placebo will be administered orally, once daily continuously for 28-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Determine recommended dose of bezuclastinib (CGT9486) in subjects with NonAdvSMTime frame: 3 months
- Part 2: Efficacy of bezuclastinib at the selected dose versus placeboTime frame: 24 Weeks
- Part 3: Safety and tolerability of bezuclastinib as assessed by number of adverse eventsTime frame: Up to 5 years
Locations
57 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Arizona
Phoenix, Arizona
One of a Kind Clinical Research Center
Scottsdale, Arizona
Modena Allergy and Asthma Clinical
La Jolla, California
Innovative Research of West Florida
Clearwater, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida
University of South Florida
Tampa, Florida
Emory University
Atlanta, Georgia
Rush University
Chicago, Illinois
Walter Reed National Military Medical Center
Bethesda, Maryland
Allervie Clinical Research
Glenn Dale, Maryland
Institute for Asthma and Allergy
Wheaton, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Washington University at St. Louis
St Louis, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Duke University
Raleigh, North Carolina
University of Cincinnati
Cincinnati, Ohio
The Ohio State University
Columbus, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
AIR Care
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Metrodora Institute of Technology
West Valley City, Utah
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Antwerp University Hospital (UZA)
Edegem, Belgium
CHU Tivoli
La Louvière, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
AP-HP- Hopital Pitie-Salpetriere
Paris, France
CHU de Toulouse - Hopital Larrey
Toulouse, France
Universitaetsklinikum Aachen, AoeR
Aachen, Germany
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
University Medical Centre Mannheim
Mannheim, Germany
Cork University Hospital
Cork, Ireland
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.